Search results for "PUVA Therapy"

showing 7 items of 7 documents

Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer.

2015

A new series of pyrazolo[3,4-h]quinolines, heteroanalogues of angelicin was conveniently prepared with a broad substitution pattern. A large number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against 5 different human tumor cell lines with GI50 values reaching the nanomolar level (14.52e0.04 mM). Selected compounds were able to photoinduce a massive cell death with the involvement of mitochondria. Their photodamage cellular targets were proteins and lipids and they did not cause any kind of DNA photodamage. This latter event is of considerable importance in the modulation of long term side effects, generally associated with the use of classical furo…

Programmed cell deathPhotodynamic therapy; Antiproliferative activity; Photosensitizing agents; Reactive oxygen species; PUVA therapyPUVA therapymedicine.medical_treatmentPhotodynamic therapyAntineoplastic AgentsAntiproliferative activityPhotodynamic therapy Antiproliferative activity Photosensitizing agents Reactive oxygen species PUVA therapyMitochondrionPhotodynamic therapychemistry.chemical_compoundStructure-Activity RelationshipAngelicinCell Line TumorDrug DiscoverymedicineStructure–activity relationshipHumansCell ProliferationPharmacologyPhotosensitizing AgentsDose-Response Relationship DrugMolecular StructureCell growthOrganic ChemistryGeneral MedicinePhotosensitizing AgentSettore CHIM/08 - Chimica FarmaceuticaFurocoumarinsBiochemistrychemistryQuinolinesPyrazolesDrug Screening Assays AntitumorReactive oxygen speciesEuropean journal of medicinal chemistry
researchProduct

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

2020

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items…

medicine.medical_specialtybusiness.industryVitiligoMEDLINETreatment optionsDermatologyGeneral MedicineVitiligomedicine.diseaselaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030220 oncology & carcinogenesisQuality of LifemedicineHumansImmunologic FactorsProspective StudiesIntensive care medicinebusinessPUVA TherapyDermatologic Therapy
researchProduct

Photoreactivity of Furocoumarins and DNA in PUVA Therapy: Formation of Psoralen−Thymine Adducts

2008

The mechanism of the [2 + 2] cycloaddition photoreaction of psoralen and a DNA nucleobase, thymine, cornerstone of the furocoumarin-based PUVA (psoralen + UVA radiation) phototherapy, has been studied by the quantum-chemical multiconfigurational CASPT2 method. Triplet- and singlet-mediated mono- and diadduct formations have been determined to take place via singlet-triplet crossings and conical intersections, correlated with the initially promoted triplet or singlet states in different possible reactive orientations. Pyroneside monoadducts are suggested to be formed in the triplet manifold of the system, and to be less prone to yield diadducts because of the properties of the monoadduct low…

Models MolecularMolecular StructurePhotochemistryFurocoumarinFicusinDNAConical intersectionPhotochemistrySurfaces Coatings and FilmsThymineNucleobasechemistry.chemical_compoundFurocoumarinschemistryFurocoumarinsMaterials ChemistrySinglet statePhysical and Theoretical ChemistryTriplet statePUVA TherapyThyminePsoralenThe Journal of Physical Chemistry B
researchProduct

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

2011

Objective  The aim of this study was to evaluate the safety and efficacy profile of pegylated interferon α-2b (PEG-IFN α-2b) in combination with photochemotherapy (PUVA) in the treatment of cutaneous T-cell lymphoma (CTCL) in comparison with standard IFN α plus PUVA. Design  Retrospective cohort study over a period of 7 years. Patients and interventions  A total of 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity and response rates associated with PEG-IFN α-2b (1.5 μg/kg weekly) plus PUVA (n = 9) or standard IFN α-2a (9 MIU 3×/week) plus PUVA (n = 8). Main outcome measures  Differences of response rates (complete/partial remission), progression-free surv…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCutaneous T-cell lymphomaDermatologymedicine.diseaseDermatologyGastroenterologyDiscontinuationchemistry.chemical_compoundInfectious DiseaseschemistryPegylated interferonInternal medicinePUVA therapyToxicitymedicinebusinessProspective cohort studyAdverse effectPsoralenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct

Incidence of non-melanoma skin cancer in patients treated with psoralen and ultraviolet A therapy.

2019

Abstract Introduction Studies reporting incidences of non-melanoma skin cancer (NMSC) are heterogeneous, depend on the geographic area of the studied population and are often short-term. The aim of this study is to determine the incidence of NMSC in patients treated with oral PUVA therapy in the Mediterranean area. Material and methods A retrospective, observational study was carried out with a sample of 234 patients treated with systemic PUVA between 1982 and 1996, carrying out a historical follow-up until May 2017. The incidence density rate of CCNM (crude and adjusted) was calculated by direct standardisation. The incidence of CCNM was compared with that reported in the general populatio…

AdultMalemedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentPopulation03 medical and health sciences0302 clinical medicinemedicineCarcinomaHumansBasal cell carcinoma030212 general & internal medicineeducationPUVA Therapyeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceAge FactorsMiddle Agedmedicine.diseaseDermatologyEpidermoid carcinomaCarcinoma Basal CellPUVA therapyCarcinoma Squamous CellObservational studyFemaleSkin cancerbusinessMedicina clinica
researchProduct